Status and phase
Conditions
Treatments
About
This is a phase I, open label study to evaluate the safety, identify the recommended dose (RD) and obtain preliminar evidence of the efficacy of allogeneic, CD19-directed Chimeric Antigen Receptor T (alloCAR-T) cells in pediatric and young adults patients with relapsed/refractory B-cell precursor Acute Lymphoblastic Leukemia (BCP-ALL).
Full description
This is a phase 1, single-center, non-randomized, open-label, dose-escalation study to evaluate the safety, identify the recommended dose (RD) and obtain preliminar evidence of the efficacy of fresh, donor-derived, CD19-directed-second-generation CAR T cells (alloCART) in pediatric and young adults patients with relapsed/refractory B-cell precursor Acute Lymphoblastic Leukemia (BCP-ALL) occurring either after allogeneic hematopoietic stem cell transplantation (alloHSCT) or before alloHSCT, in case of refractory disease and availability of a HLA-fully matched donor.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Patient Inclusion Criteria:
Patients with a diagnosis of CD19 expressing B ALL relapse, and one of the following:
CD19+ count ≥ 50 cells/mcl and/or Minimal Residual Disease (MRD) ≥ 10^-4.
Voluntary informed consent. For subjects < 18-years old their legal guardian must give informed consent. Pediatric subjects will be included in age-appropriate discussion and verbal assent will be obtained for those greater than or equal to 12 years of age, when appropriate.
Clinical performance status: patients > 16 years of age: Karnofsky greater than or equal to 60%; patients ≤ 16 years of age: Lansky score than or equal to 60%.
Patients of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study and for 4 months after receiving the lymphodepletion regimen.
Females of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects on the fetus.
Patients Exclusion Criteria:
Pregnant or lactating women.
Severe, uncontrolled active intercurrent infections.
HIV, or active HCV and/or HBV infection.
Life-expectancy < 6 weeks or rapidly progressive disease that in the evaluation of the investigator would compromise ability to complete study therapy.
Hepatic function: inadequate liver function defined as total bilirubin > 4x upper limit of normal (ULN) or transaminase (ALT and AST) > 6x ULN.
Renal function: serum creatinine >3x ULN for age.
Blood oxygen saturation < 90%.
Cardiac function: left ventricular ejection fraction lower than 45% by ECHO.
Congestive heart failure, cardiac arrhythmia, psychiatric illness, or social situations that would limit compliance with study requirements or in the opinion of the PI would pose an unacceptable risk to the subject.
Presence of active, grade 2-4 acute or chronic Graf versus Host Disease (GvHD) requiring steroid therapy or other immune-suppressive treatment.
Relapse occurring before 60 days after alloHSCT.
Concurrent or recent prior therapies, before infusion:
i. systemic steroids (at a dose of ≥ 2 mg/kg prednisone) in the 2 weeks before infusion of CD19-CAR_Lenti_ALLO cells . Recent or recurrent use of inhaled/topical/non-absorbable steroids is not exclusionary.
ii. systemic chemotherapy in the 2 weeks preceding infusion of CD19-CAR_Lenti_ALLO cells .
iii. anti-thymocyte globulin (ATG) or Alemtuzumab (Campath®)in the 8 weeks preceding infusion of CD19-CAR_Lenti_ALLO cells .
iv. immuno-suppressive agentis in the 2 weeks preceding infusion of CD19-CAR_Lenti_ALLO cells
v. radiation therapy must have been completed at least 2 weeks before infusion of CD19-CAR_Lenti_ALLO cells .
vi. other anti-neoplastic investigational agents currently administered or within 30 days prior to infusion of CD19-CAR_Lenti_ALLO cells (i.e, start of protocol therapy).
vii. Exceptions:
Donor Eligibility Criteria
Conventional criteria for the eligibility of allogeneic donors will be adopted for the evaluation of cell donors, before apheresis, as required by law.
Primary purpose
Allocation
Interventional model
Masking
24 participants in 1 patient group
Loading...
Central trial contact
Franco Locatelli, MD, PhD; Francesca del Bufalo, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal